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The mortality rate of patients who develop acute kidney
injury during sepsis nearly doubles. The effectiveness of
therapy is hampered because it is usually initiated only after
the onset of symptoms. As renal microvascular failure during
sepsis is correlated with the generation of reactive nitrogen
species, the therapeutic potential of resveratrol, a polyphenol
vasodilator that is also capable of scavenging reactive
nitrogen species, was investigated using the cecal ligation
and puncture (CLP) murine model of sepsis-induced acute
kidney injury. Resveratrol when given at 5.5 h following CLP
reversed the decline in cortical capillary perfusion, assessed
by intravital microscopy, at 6h in a dose-dependent manner.
Resveratrol produced the greatest improvement in capillary
perfusion and increased renal blood flow and the glomerular
filtration rate without raising systemic pressure. A single dose
at 6 h after CLP was unable to improve renal microcirculation
assessed at 18h; however, a second dose at 12h significantly
improved microcirculation and decreased the levels of
reactive nitrogen species in tubules, while improving renal
function. Moreover, resveratrol given at 6, 12, and 18h
significantly improved survival. Hence, resveratrol may
have a dual mechanism of action to restore the renal
microcirculation and scavenge reactive nitrogen species,
thus protecting the tubular epithelium even when
administered after the onset of sepsis.
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Sepsis is a disseminated inflammatory response elicited by a
microbial infection1 and is the major cause of death among
critically ill patients.2,3 Approximately 750,000 patients in the
US2 and 18 million people worldwide are affected annually.4
Unfortunately, the foundation of treatment for septic patients
remains nonspecific supportive care.1 Early goal-directed
therapy, consisting of fluid resuscitation and supportive
treatment to protect organ perfusion, can improve survival;5
however, mortality rates still approach 30% even among
adequately resuscitated patients.6,7 It is becoming increas-
ingly clear that restoring the macrocirculation is not always
sufficient to adequately restore the microcirculation and
preserve organ function. This is a critical issue because the
severity of microvascular dysfunction correlates with patient
mortality.8,9 Development of acute kidney injury (AKI) is
common during severe sepsis and more than doubles the
mortality rate to nearly 75%.10 Studies in rodent models have
shown that the renal microcirculation is compromised
during the development of sepsis.11–15 Thus, there is a
pressing need for the development of novel therapeutic
approaches to treat sepsis-induced AKI, which can restore
perfusion of the renal microcirculation even when initiated
after the onset of sepsis.6,16,17
Hallmarks of sepsis include excessive generation of nitric
oxide (NO),10 endothelial injury, and a loss of vascular
reactivity,6,18 resulting in areas of local microcirculatory
hypoperfusion6,17 and areas of tissue hypoxia. This leads to a
peritubular pro-oxidant microenvironment favoring the
generation of reactive oxygen and reactive nitrogen species
(RNS).13,19,20 The reaction of NO with superoxide generates
peroxynitrite, a powerful oxidizing RNS that causes protein
nitration, DNA damage, and mitochondrial dysfunction, all
of which have been suggested to be critical to the progression
of AKI during sepsis.10,12,13,21 Thus, RNS generation
occurring later in the progression of sepsis could be a
suitable therapeutic target for agents administered after the
onset of sepsis,12,22 but this has not yet been directly studied.
Resveratrol (RES), a polyphenolic nutraceutical with
vasodilatory and antioxidant activities, has been shown to
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be protective in various disease models,23,24 including septic
rats, when administered before or at the very onset of
sepsis.25,26 We recently showed that RES is a potent scavenger
of peroxynitrite and can protect tubular epithelial cells from
the damaging effects of peroxynitrite in vitro.27 To investigate
the therapeutic potential of RES, we studied its effects on
renal macro- and microcirculation and tubular epithelial
RNS generation during sepsis. In the first series of
experiments, we determined the acute dose effects of RES
on the peritubular microcirculation, as well as its acute effects
on renal blood flow (RBF) and glomerular filtration rate
(GFR). Thereafter, to more closely mimic the clinical
setting,28 we used a delayed treatment regimen initiated after
the onset of septic shock to examine the effects of RES on
peritubular capillary failure, RNS generation, renal function,
and survival.
RESULTS
Acute effects of RES administration on renal cortical
microcirculation during sepsis
A hallmark of both clinical sepsis and experimental animal
models of sepsis is severe microvascular dysfunction.6,29
Using intravital video microscopy (IVVM), we categorized
the cortical distribution of peritubular capillary perfusion as
continuous, intermittent, or no flow. At 6 h, sham control
mice had a high percentage of continuously perfused renal
cortical capillaries (79±2%) and only a small percentage of
capillaries with no flow (Figure 1). In contrast, at 6 h post
cecal ligation and puncture (CLP), the percentage of
capillaries with continuous perfusion was reduced to
34±5% and the percentage of capillaries with no perfusion
was increased to 45±5%. The acute effects of RES on the
renal microcirculation were tested at doses of 3, 10, 30, and
100mg/kg (intraperitoneal, i.p.) administered at 5.5 h post
sham or CLP surgery. Capillary perfusion was then assessed
at 6 h. Although the highest dose of RES tested (100mg/kg)
caused no obvious signs of toxicity in sham mice, this dose
was lethal in CLP mice within 30min (100% mortality,
n¼ 3). Therefore, this dose was omitted from all subsequent
studies. These categorical data were analyzed using the
Hotelling’s T2-test (see Materials and Methods) to compare
the distribution between groups. Doses of 10 and 30mg/kg
reversed the decline in capillary perfusion in CLP mice
(Figure 1a). As a control, RES (30mg/kg, i.p.) was
administered to sham mice and had no effect on capillary
perfusion (data not shown).
As categorical perfusion data do not address nutritive
capillary flow, mean red blood cell (RBC) velocity was
measured in continually flowing capillaries from the same
videos analyzed in Figure 1a. At 6 h, the measured mean
RBC velocity in sham mice was 374±20 mm/s. CLP caused
a significant reduction in mean RBC velocity compared
with sham (126±16 mm/s; Po0.05). Resveratrol produced
a bell-shaped dose–response curve for restoring RBC velo-
city (Figure 1b), with 10mg/kg being the most efficacious
dose tested.
Acute effects of RES administration on mean arterial pressure
(MAP) and heart rate (HR)
MAP in CLP decreased from 111±7mmHg before surgery
to 77±7mmHg (Po0.05) at 6 h post surgery, whereas
MAP in sham did not change significantly (115±7 vs.
111±6mmHg). Resveratrol at doses of 3, 10, or 30mg/kg
administered at 5.5 h did not affect MAP at 6 h in CLP,
nor did RES at a dose of 30mg/kg affect MAP in sham
(Figure 2a). HR in CLP decreased from 558±49 b.p.m.
before surgery to 331±18 b.p.m. (Po0.05) at 6 h, whereas
HR in sham did not change significantly (629±27 vs.
561±4 b.p.m.). Resveratrol at doses of 3, 10, or 30mg/kg
administered at 5.5 h did not affect HR at 6 h in CLP,
but 30mg/kg did increase HR slightly in sham (Po0.05;
Figure 2b). These data suggested that the increase in
microcirculatory perfusion in CLP mice observed following
RES administration was not the result of an increase in
MAP or HR.
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Figure 1 |Acute effects of resveratrol (RES) on renal cortical
microcirculation at 6 h. Cecal ligation and puncture (CLP) surgery
caused a significant reduction in the categorical perfusion (a) and
mean red blood cell (RBC) velocity (b) of the peritubular capillaries
at 6 h. Resveratrol administration at 5.5 h acutely improved both
categorical perfusion and mean RBC velocity measured at 6 h,
with 10mg/kg (intraperitoneal, i.p.) being the most efficacious
dose tested to restore RBC velocity. *Po0.05 compared with
shamþ vehicle; #Po0.05 compared with shamþ vehicle and
CLPþ vehicle; n¼ 6–7.
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Acute effect of RES administration on RBF and GFR
As RBF is a major determinant of renal microcirculatory
perfusion, the effects of RES on RBF were determined. At
5.5 h after CLP or sham surgery, a baseline measurement
of RBF was obtained and RES (10mg/kg) or vehicle was
administered via the penile vein. A second measurement
of RBF was obtained at 6 h. At 5.5 h, RBF was significantly
lower in CLP mice compared with sham (1.1±0.2 versus
3.4±0.3ml/min per g, respectively; Po0.05; Figure 3a).
At 30min post treatment, vehicle had no effect on RBF in
CLP mice and RES had no effect on RBF in sham mice. In
contrast, RES significantly raised RBF to 2.6±0.6ml/min per g
(Po0.05 compared with CLP), a value not different from
that seen in sham.
To assess the acute effects of RES administration on renal
function, GFR was measured in conscious mice beginning at
6 h after CLP or sham surgery. CLP mice showed a signi-
ficantly lower GFR at 6 h compared with sham (0.36±0.04
versus 1.03±0.07ml/min per g; Po0.05). Administration of
RES 30min before GFR measurement in CLP mice (Figure 3b)
resulted in an acute improvement in GFR (0.54±0.04ml/min
per g; Po0.05 compared with CLP).
Effects of delayed administration of RES on renal
microcirculation at 18 h
At 18 h following CLP, capillary perfusion and mean RBC
velocity were still low relative to sham (Figure 4). A single
dose of RES (10mg/kg, i.p.) administered at 6 h was unable
to maintain perfusion through 18 h. However, a second dose
administered at 12 h prevented the change in the distribu-
tion of cortical perfusion and the decline in RBC velocity
(Figure 4a and b).
Effects of delayed administration of RES on RNS generation
in the renal tubules
As oxidation of dihydrorhodamine-1,2,3 is not absolutely
selective for the RNS peroxynitrite,30,31 two complementary
approaches were used to detect the generation of peroxyni-
trite: (1) oxidation of dihydrorhodamine-1,2,3 to rhodamine
and (2) detection of immunoreactive nitrotyrosine–protein
adducts.32 We previously reported that rhodamine fluores-
cence appears in tubules bordered by capillaries with no flow,
and that both rhodamine fluorescence and nitrotyrosine–-
protein adducts appear in the vacuoles of injured tubules.12
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Figure 2 |Acute effects of resveratrol (RES) on mean arterial
pressure (MAP) and heart rate (HR) at 6 h. Cecal ligation and
puncture (CLP) surgery resulted in a significant decrease in MAP
(a) and HR (b) at 6 h. Resveratrol at any of the tested doses had
no significant (NS) effect on MAP or HR in CLP mice. However,
RES (30mg/kg, intraperitoneal, i.p.) slightly increased HR in sham.
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Figure 3 |Acute effects of resveratrol (RES) on renal blood
flow (RBF) and glomerular filtration rate (GFR) at 6 h. Cecal
ligation and puncture (CLP) caused a significant reduction in
both RBF (a) and GFR (b) at 6 h. Resveratrol (10mg/kg, i.v.)
administered at 5.5 h restored RBF and improved GFR at 6 h.
*Po0.05 compared with sham and #Po0.05 compared with sham
and CLP; n¼ 7–11 for (a) and n¼ 4–5 for (b).
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Representative pseudocolored images of rhodamine fluores-
cence from the sham, CLP, and CLPþRES (two doses)
groups were captured from the cortices of live mice using
IVVM and are presented in Figure 5a–c, respectively, along
with the quantification of pixel intensity in Figure 5d. Only
weak rhodamine fluorescence was observed in sham at 18 h
(Figure 5a), but rhodamine fluorescence was increased in
tubules from CLP mice (Figure 5b). A single dose of RES
(10mg/kg) administered at 6 h significantly reduced rhoda-
mine fluorescence in CLP mice, as did two doses (Figure 5d).
Representative images of nitrotyrosine staining from the
sham, CLP, and CLPþRES (two doses) groups are presented
in Figure 5e–g, respectively. Sham tissue displayed only weak
staining for nitrotyrosine–protein adducts. In contrast, at
18 h after CLP, nitrotyrosine staining was intense in renal
tubules but not in glomeruli. No staining was observed in the
nonspecific binding control (not shown), where the anti-
nitrotyrosine antibody was preincubated with 10mmol/l
nitrotyrosine before use. Two doses of RES blocked the
formation of nitrotyrosine–protein adducts. Both indepen-
dent methods of detection (ongoing generation with
rhodamine and cumulative generation with nitrotyrosine
immunohistochemistry) indicated that RES reduced renal
levels of RNS.
Effects of delayed administration of RES on systemic NO
generation
The systemic inflammatory response following CLP is
associated with early release of cytokines such as tumor
necrosis factor-a22,33 and increased generation of NO.13 To
help address whether RES decreased RNS levels by decreasing
NO generation, the effects of RES on serum NO levels were
determined by measuring serum nitrateþ nitrite concentra-
tion. At 18 h, levels in CLP were significantly higher than that
in sham (166±16 versus 60±5 mmol/l; Po0.05). Two
doses of RES (10mg/kg) administered at 6 and 12 h did
not affect nitrateþ nitrite concentration (181±20 mmol/l;
P40.05 compared with CLP).
Effects of delayed administration of RES on renal
morphological damage at 18 h
At 18 h, morphological changes in the CLP group were
characterized by mild brush border loss, tubular degenera-
tion, and vacuolization in the early segments of proximal
tubules (Figure 6b). The two-dose RES treatment regimen
reduced the morphological damage and the tubular injury
score (Figure 6c and d).
Effects of delayed administration of RES on renal function
at 18 h
As RES was shown to improve renal microcirculation, RNS
generation, and tubular morphology, we investigated the
ability of RES to protect against the development of AKI. At
18 h post CLP, two clinically used markers of AKI, blood urea
nitrogen, and creatinine, were increased in CLP mice (Figure
7a and b). Although the single dose of RES (10mg/kg)
administered at 6 h reduced only serum creatinine levels
(data not shown), two doses of RES administered at 6 and
12 h post CLP significantly reduced both markers (Figure 7a
and b). As serum creatinine is no longer considered a reliable
marker of GFR and renal function in mice,34 GFR and RBF
were measured at 18 h. CLP mice showed a significant
reduction in both GFR and RBF compared with sham at 18 h
(Figure 7c and d). Administration of two doses of RES
significantly improved (doubled) GFR from 0.20±0.06ml/
min per g in CLP to 0.41±0.05ml/min per g in CLPþRES
(Po0.05) and significantly improved (doubled) RBF from
1.1±0.1ml/min per g in CLP to 2.4±0.1ml/min per g in
CLPþRES (Po0.05). However, RES did not restore RBF or
GFR to sham levels.
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Figure 4 | Effect of delayed resveratrol (RES) administration on
renal cortical microcirculation at 18 h. At 18 h post cecal
ligation and puncture (CLP), categorical perfusion (a) and mean
red blood cell (RBC) velocity (b) remained low compared with 6 h
(Figure 1). A single dose of RES (10mg/kg, intraperitoneal, i.p.)
administered at 6 h did not improve the renal microcirculation
at 18 h. However, administration of an additional dose of RES
(10mg/kg, i.p.) at 12 h resulted in a complete restoration of both
categorical capillary perfusion (a) and mean RBC velocity (b) at
18 h. *Po0.05 compared with sham and #Po0.05 compared with
sham and CLP; n¼ 6–7.
Kidney International (2012) 81, 370–378 373
JH Holthoff et al.: Resveratrol and sepsis-induced acute kidney injury o r ig ina l a r t i c l e
Effects of delayed administration of RES on survival
The ability of RES to improve renal microcirculation and
restore renal function led us to investigate the potential of
RES to increase survival following CLP using a clinically
relevant dosing protocol starting 6 h after the induction of
sepsis (CLP). Two groups of mice were subjected to CLP.
Beginning at 6 h, one group received vehicle at 6, 12, and
18 h, whereas the other group received RES (10mg/kg, i.p.) at
6, 12, and 18 h. Using a defined criteria of impending
mortality (core temperature of o28 1C35), RES significantly
improved survival (Figure 8; Po0.001 using the Mantel–Cox
log rank test).
DISCUSSION
Microvascular dysfunction is a strong predictor of death
among septic patients.29 In both lipopolysaccharide20,36 and
CLP12–14 models of sepsis-induced AKI, peritubular capillary
hypoperfusion occurs rapidly and is associated with sub-
sequent generation of peroxynitrite in the renal epithelium.
As we recently showed that RES is a potent scavenger of
peroxynitrite and can protect tubular epithelial cells from the
damaging effects of peroxynitrite in vitro,27 we studied the
therapeutic potential of RES using a murine model of sepsis
and a clinically relevant treatment regimen.
It is becoming increasingly clear that early goal-directed
therapy has the greatest chance of improving the outcome in
patients with severe sepsis.37,38 Moreover, targeting the
microcirculation to preserve/restore perfusion would not
only lessen injury but also promote organ recovery.39,40
Unfortunately, effective therapy in the septic patient is
hampered because therapy usually begun only after the onset
of symptoms (i.e., systemic inflammatory response syn-
drome).28 In this study, we examined the acute effects of RES
on CLP-induced AKI using a clinically relevant course of
therapy that began after the development of septic shock and
the decline in renal microcirculatory perfusion.
We chose to examine the effects of RES at 6 h post CLP,
a time when systemic inflammation had already begun22
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and peritubular capillary perfusion was severely reduced.13
Within 30min of administration, RES restored both measures of
peritubular capillary perfusion: categorical perfusion (an index
of overall perfusion) and RBC velocity. Surprisingly, in CLP
mice, RES exhibited a bell-shaped dose–response curve.
Doses higher than 10mg/kg were less effective in restoring
velocity or, in the case of the 100mg/kg dose, lethal within
30min. It is important to note that RES was administered
i.p. rather than orally, where extremely high oral doses
exhibit little signs of toxicity, presumably because of the
low bioavailability of oral RES.41 The mechanisms of such a
rapid lethal toxicity in CLP mice at the 100mg/kg dose is
unknown but likely related to the fact that the mice were
in septic shock as this dose of RES did not produce signs
of toxicity in sham mice.
CLP also induced a rapid decline in MAP within the first
6 h, approaching the lower limit of the reported renal
autoregulatory pressure in the mouse necessary to maintain
RBF and GFR.42 The state of RBF during sepsis-induced AKI
is controversial. For example, in a sheep model of Escherichia
coli infusion, RBF increases over time,43 whereas autologous
fecal peritonitis in pigs, a model more closely related to CLP,
showed a slow decline in RBF as MAP decreased.44 We found
that RBF and GFR were significantly reduced at 6 h,
paralleling the decline in MAP. It was striking how rapidly
RES increased both RBF and GFR in our model. This effect
on RBF was likely due to a decrease in renal vascular
resistance as RES did not raise MAP or HR and had no effect
on RBF in sham mice with normal MAP. One possible
mechanism for the observed rapid increase in RBF was the
activation of potassium channels45,46 present in both afferent
and efferent arterioles.47 Further studies are needed to
directly address the mechanism of decreased RBF in septic
mice and the ability of RES to restore RBF. Although RES was
able to acutely restore RBF, it only partially improved GFR,
suggesting that RBF was not the only determinant of GFR.
CLP causes renal capillary leakage by 6 h14 and this could
have contributed to the reduction in GFR1 and reduced
efficacy of RES. Nevertheless, these findings support the
notion that agents that reduce renal vascular resistance
during sepsis could be beneficial in this hemodynamic
(prerenal) form of AKI.48
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Figure 7 | Effects of delayed resveratrol (RES) administration
on renal function at 18 h. At 18 h post cecal ligation and
puncture (CLP), mice showed elevated levels of blood urea
nitrogen (a) and serum creatinine (b), as well as significantly
reduced renal blood flow (RBF) (c) and glomerular filtration rate
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Figure 8 | Effects of delayed resveratrol (RES) administration
on survival. Administration of RES (10mg/kg, i.p) to cecal ligation
and puncture (CLP) mice at 6, 12, and 18 h resulted in a significant
improvement in survival compared with vehicle-treated mice
(*Po0.01; Mantel–Cox log-rank test; n¼ 10/group).
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When sepsis is associated with hypotension and decreased
RBF, an increase in renal vascular resistance is a compensa-
tory mechanism to help maintain GFR, albeit at the potential
cost of peritubular capillary perfusion.49 The decline in
capillary perfusion appeared to be highly dependent on RBF
as restoring RBF increased both the number of capillaries
perfused and the quality of nutritive flow, despite only a
modest improvement in GFR. On the basis of the acute
dose–response effects of RES, the dose of 10mg/kg was
evaluated for its ability to prevent AKI, which develops
between 18 and 24 h in this model.11,22 Against measures of
capillary perfusion, RNS generation, and serum blood urea
nitrogen/creatinine, a single dose of RES administered at 6 h
improved only some of these markers of injury at 18 h.
However, when a second dose was administered at 12 h, there
was significant improvement in all markers of renal injury;
when mice were dosed through 18 h, 48-h survival was
significantly improved, although dosing was delayed until
after the onset of renal hemodynamic failure. The ineffec-
tiveness of the single dose to restore perfusion at 18 h may be
because of the extremely short half-life of RES (B30min) in
rodents,50,51 which supports the finding that multiple dosing
with RES was necessary to prevent renal injury. These
findings also raise the possibility that continuous infusion
may allow for a lower effective dose and thus lessen the
chance for toxicity.
Peritubular capillary hypoperfusion can lead to a hypoxic
pro-oxidant microenvironment favoring the generation of
RNS.12,20 This can lead to epithelial injury (swelling, cast
formation, cell sloughing), which can disrupt tubular–
glomerular feedback regulation of GFR52 and perpetuate
microcirculatory failure.53 The ability of RES to scavenge
peroxynitrite in renal tubular epithelial cells27 is likely
another mechanism of protection; however, the potential
for RES to reduce peroxynitrite levels indirectly by scaveng-
ing superoxide cannot be ruled out.54 Interestingly, even
the single dose of RES administered at 6 h reduced the
levels of RNS generation by the tubular epithelium at
18 h. This finding supports the notion that RES meta-
bolites (glucuronides and sulfates) retain a degree of
RNS-scavenging activity.23,55 Resveratrol may have also
upregulated endogenous antioxidant defenses;25,26,56 how-
ever, this effect is less likely given the short treatment time
and rapid response. Recently, RES was shown to increase
mitochondrial biogenesis and/or protect the mitochondria
through activation of the protein deacetylase, Sirtuin 1.57,58
This potential additional mechanism warrants further
investigation because of the critical role of mitochondrial
dysfunction in the development of multiple organ failure
during sepsis.59
Although these studies cannot distinguish between the
relative roles of hypoperfusion and oxidant generation, the
data suggest that interrupting the cycle of renal injury by
restoring perfusion as early as possible or by scavenging
oxidants may allow the tubular epithelium to recover,
lessening AKI and improving survival. Drugs such as RES
with this dual mechanism of action (restoration of perfusion
and RNS scavenging) may provide a novel therapeutic option
for the treatment of sepsis-induced AKI because protection
may be possible even when administered after the onset of
sepsis.
MATERIALS AND METHODS
CLP model of sepsis
All animals were housed and handled in accordance with the
National Institute of Health Guide for the Care of Laboratory Animals
with approval from an internal animal care and use committee. CLP
was performed on male C57/BL6 mice (Harlan, Indianapolis, IN)
aged 39–40 weeks as described previously.12,13 Under isoflurane
anesthesia, 1.5 cm of the cecal tip was ligated using a 4-0 silk suture
and punctured twice with a 21-gauge needle. An approximately
1-mm column of fecal material was expressed. In sham-operated
mice (sham), the cecum was isolated but neither ligated nor
punctured. Following surgery all mice received 1ml of prewarmed
saline and were placed in individual cages on a heating pad. Mice
studied at time points longer than 6 h were given imipenem/
cilastatin (14mg/kg) and 1.5ml of normal saline (40ml/kg,
subcutaneous) at 6 h.
Administration of RES
Fresh solutions of trans-resveratrol (Cayman Chemical Company,
Ann Arbor, MI) were prepared in dimethyl sulfoxide (vehicle), kept
in the dark, and diluted in normal saline just before use. To assess
the very acute effects of RES, mice were administered RES at 5.5 h
and studied at 6 h. When mice were studied at 18 h, RES was
administered at 6 h post CLP and then again at 12 h because of the
relative short half-life of RES in rodents (B30min50,51). For the
48-h survival study, RES was administered through the development
of renal injury by dosing at 6, 12, and 18 h.12
Intravital video microscopy
IVVM was performed as described previously.12,13,20 Briefly,
following anesthesia, FITC-labeled dextran (500 kDa, Sigma,
St Louis, MO) and dihydrorhodamine-1,2,3 (DHR, Invitrogen,
Carlsbad, CA) were administered through the penile vein to
visualize the capillary vascular space and detect RNS generation,
respectively. The doses of FITC-dextran and DHR were 1.4 mmol/kg
and 0.8mg/kg, respectively, in 2.1ml/kg normal saline. The left
kidney was exposed by a flank incision and positioned on a glass
stage above an inverted Zeiss Axiovert 200M fluorescent microscope
equipped with an Axiocam HSm camera (Zeiss, Jena, Germany).
Video images of 10 s (approximately 30 frames/s) at  200 magni-
fication were acquired from five randomly selected, nonoverlapping
fields of view. Body temperature was maintained at 36–37 1C with a
warming lamp.
Assessment of renal microcirculation
Capillaries were randomly selected from each of the video images
collected during IVVM and categorized as ‘continuous flow’ when
RBC movement was continuous; ‘intermittent flow’ when RBC
movement stopped or reversed; or ‘no flow’ when no RBC move-
ment was observed. Approximately 150 capillaries were analyzed
for each animal. Data were expressed as the percentage of vessels in
each of the three categories. RBC velocity was calculated in continu-
ously flowing capillaries by measuring the distance traveled by
a single RBC over time. Data were expressed as mm/s.
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Detection of RNS generation using IVVM
DHR is preferentially oxidized to fluorescent rhodamine by
peroxynitrite and perhaps other reactive oxygen species/RNS species
but not by superoxide.30,31 Rhodamine fluorescence was visualized
at 535 nm excitation and 590 nm emission. Still images exposed for
500ms were captured from the fields of view used to determine
capillary perfusion. Fluorescence intensity was measured by ImageJ
(NIH, Bethesda, MD) after first subtracting background fluores-
cence intensity. Data were expressed as arbitrary units/mm2.
Measurement of MAP and HR in conscious mice
MAP and HR were monitored continuously in conscious mice using
biotelemetry. Transmitters (Data Sciences International, Minneapo-
lis, MN) were implanted into the carotid artery under isoflurane
anesthesia and the animals were allowed to recover for 48 h.
Cardiovascular parameters were recorded for 10 s every 5min. At
5.5 h following surgery, mice were administered RES or vehicle.
Measurement of RBF
Under isoflurane anesthesia, the right renal artery was isolated from
the vein and a Transonic Systems (Ithaca, NY)-calibrated 0.5 PSL
renal artery Doppler flow probe was positioned around the renal
artery. RBF was recorded after the flow stabilized (approximately
10min after placement of the probe) using PowerLab and LabChart
software (AD Instruments, Dunedin, New Zealand). Resveratrol
(10mg/kg) or vehicle was administered through the penile vein.
Body temperature was maintained at 36–37 1C with a heating lamp.
Data were expressed in ml/min per g kidney weight.
Measurement of GFR
GFR was measured using the single bolus FITC-inulin clearance
method.60 Briefly, a 5% solution was prepared by dissolving FITC-
inulin (Sigma, St Louis, MO) in normal saline. The solution was
injected through the penile vein at a dose of 3.74ml/g. Blood (25 ml)
was collected into heparinized capillary tubes at 3, 7, 10, 15, 35, 55,
75, 90, and 120min post injection. FITC-inulin in serum was
measured at 485 nm excitation and 538 emission and quantified
against a known concentration. Inulin clearance was calculated
using a two-phase decay nonlinear regression analysis. GFR was
calculated using the fast and slow phases of inulin clearance after
normalizing to the combined weight of both kidneys.
Measurement of total serum NO levels
Serum nitrateþ nitrite levels were determined using the Total Nitric
Oxide Assay Kit (Assay Designs, Ann Arbor, MI) as directed by the
manufacturer and concentration expressed as in mmol/l.
Measurement of serum creatinine and blood urea nitrogen
concentration
Serum creatinine levels and blood urea nitrogen were measured
using the QuantiChrom Creatinine Assay kit and Urea Assay kit,
respectively (BioAssay Systems, Hayward, CA).
Immunohistochemistry staining for nitrotyrosine
Nitrotyrosine–protein adducts were detected using a polyclonal anti-
nitrotyrosine antibody (Millipore, Billerica, MA) diluted 1:1200 in
1% bovine serum albumin, 0.5% milk in 1 Tris-buffered saline,
pH 7.6, as described previously.12 Preincubation of the anti-
nitrotyrosine antibody with 10mmol/l nitrotyrosine was used as
the nonspecific binding control.
Histology
The periodic acid–Schiff-stained sections were scored in a blinded,
semiquantitative manner. For each animal, at least 10 high-power
( 400) fields were examined. The percentage of tubules that
displayed cellular necrosis, loss of brush border, cast forma-
tion, vacuolization, and tubule dilation was scored as follows:
0¼ none, 1¼o10%, 2¼ 11–25%, 3¼ 26–45%, 4¼ 46–75%, and
5¼476%.
Survival study
Mice subjected to CLP surgery were administered either RES
(10mg/kg, i.p.) or vehicle at 6, 12, and 18 h following CLP and
monitored for 48 h. Core body temperature was used as an indicator
of pending mortality35 and was measured every 6 h using a rectal
probe. Mice were considered as non-survivors if they died or had to
be killed because of two consecutive readings of core temperature
below 28 1C.
Statistical analysis
Data, presented as mean±s.e.m., were analyzed using Prism 5.0
(GraphPad Software, San Diego, CA). Before analysis of categorical
perfusion, the data were transformed using isometric log ratio
transformations. Hotelling’s T2-test was then used to calculate test
statistics between pairs of groups, and permutation tests were used
to calculate P-values for each comparison (Figure 1a and 4a). Renal
tubular injury scores were analyzed using the nonparametric
Kruskal–Wallis test, followed by the Dunn multiple comparison test
(Figure 6d). Survival curves (Figure 8) were analyzed using a
Mantel–Cox log rank test. For all other data, Student’s t-test was
used when two groups were compared, and a one-way analysis of
variance followed by the Newman–Keuls post-hoc test was used when
three or more groups were compared. A P-value o0.05 was
considered significant.
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